{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.73","upperLimit":"7.43","value":"6.08"},{"groupId":"OG001","lowerLimit":"4.70","upperLimit":"7.49","value":"5.62"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"259"},{"groupId":"OG001","value":"263"}],"units":"Participants"}],"description":"PFS was defined as time from date of randomization to either progression of disease (PD), death due to any cause, whichever occurs first. IMWG criteria for PD: Increase of 25% from lowest response value in any one of the following: Serum M component (absolute increase must be \\>=0.5 gram per deciliter (g/dL), Urine M-component (absolute increase must be \\>=200 mg/24 hours), Participants without measurable serum and urine Mprotein levels: difference between involved and uninvolved free light chain (FLC) levels (absolute increase must be \\>10 milligrams per deciliter (mg/dL), participants without measurable serum and urine M-protein levels and without measurable disease by FLC levels, bone marrow PC% (absolute percentage must be \\>=10%), definite development of new bone lesions or soft tissue plasmacytomas or increase in size of bone lesions or tissue plasmacytomas and development of hypercalcemia (serum calcium \\>11.5 mg/dL) that can be attributed solely to PC proliferative disorder.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received daratumumab intravenous infusion (Dara IV) 16 milligrams per kilogram (mg/kg) once weekly in Cycle 1 and 2, every 2 weeks in Cycle 3 to 6, every 4 weeks thereafter until disease progression, unacceptable toxicity, withdrawal of consent, the investigator decides to stop treatment, or the start of subsequent anticancer therapy. The duration for each cycle was 28 days.","id":"OG000","title":"Daratumumab IV"},{"description":"Participants received daratumumab 1800 mg subcutaneous injection (Dara SC) co-formulated with recombinant human hyaluronidase (rHuPH20) 2000 Units per milliliter (U/mL), once weekly in Cycle 1 and 2, every 2 weeks in Cycle 3 to 6, every 4 weeks thereafter until disease progression, unacceptable toxicity, withdrawal of consent, the investigator decides to stop treatment, or the start of subsequent anticancer therapy. The duration for each cycle was 28 days.","id":"OG001","title":"Daratumumab SC"}],"paramType":"MEDIAN","populationDescription":"ITT population included all the randomized participants.","reportingStatus":"POSTED","timeFrame":"Up to 3 years","title":"Progression Free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"Months"}